Esometa LSR Capsule is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties, facilitating enhanced gastric motility and symptomatic relief in conditions such as functional dyspepsia, gastroesophageal reflux disease (GERD), and delayed gastric emptying. Esomeprazole, a proton pump inhibitor (PPI), effectively suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, thereby providing symptomatic relief and promoting mucosal healing in acid-related disorders including GERD, peptic ulcer disease, and Zollinger-Ellison syndrome. The synergistic action of these agents addresses both motility dysfunction and acid hypersecretion, offering comprehensive therapeutic benefits. Esometa LSR Capsule is indicated for patients presenting with symptoms of reflux esophagitis, non-ulcer dyspepsia, and other acid-peptic conditions accompanied by impaired gastric motility. It should be administered under medical supervision, considering contraindications such as hypersensitivity to components, and used cautiously in patients with renal or hepatic impairment. Adverse effects may include headache, dizziness, diarrhea, and extrapyramidal symptoms. Patient adherence to prescribed dosage and duration is essential to optimize clinical outcomes and minimize potential side effects.